---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-26-000147"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2026-07-31T11:03:47+00:00"
generated_at: "2026-07-31T11:05:15.331381+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moderna Q2 net loss $(0.8)B, EPS $(1.97); norovirus vaccine misses interim endpoint

## Summary
- Q2 revenue $145M (flat YoY); GAAP net loss $(0.8)B, EPS $(1.97) vs $(2.13) in Q2 2025.
- 2026 guidance: targeting up to 10% revenue growth; year-end cash improved to $4.7-5.2B; R&D expense lowered to ~$2.9B.
- Norovirus vaccine mRNA-1403 failed early success criteria at Phase 3 interim; enrolling additional cohort.
- mFLUSIVA (flu vaccine) PDUFA date Aug 5, 2026; potential fifth approved product.
- Appointed Ester Banque as CCO and Michael McDonnell to Board.

## SEC filing metadata
- accession: 0001682852-26-000147
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2026-07-31T11:03:47+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/0001682852-26-000147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/mrna-20260731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-26-000147
- JSON: https://secwatch.observer/filing/0001682852-26-000147.json
- Plain text: https://secwatch.observer/filing/0001682852-26-000147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.